Hepatic sinusoidal obstruction syndrome due to herbal ingestion in South African children - An 8 year review

Similar documents
Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association

Natural history of α-1-atd in children

Karen A. Hicks, M.D. Medical Officer Division of Cardiovascular and Renal Products Center for Drug Evaluation and Research, FDA

Liver Disease in Cystic Fibrosis

HIV/AIDS and the Liver : interlinking challenges

AMR in Liver Transplantation: Incidence

Metabolic diseases of the liver

Gastrointestinal System: Accessory Organ Disorders

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver

Good afternoon. Thanks, John, very much for the invitation to be here today. I am delighted to discuss elevated transaminases in the setting of heart

CHAPTER 1. Alcoholic Liver Disease

Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark

How to Approach a Medical Liver Biopsy. 9 th Bryan Warren School of Pathology Pancreatic and Liver Pathology. Sarajevo, 6 th -7 th November 2015

Digestive system L 4. Lecturer Dr. Firdous M. Jaafar Department of Anatomy/Histology section

Pathology of the Liver and Biliary Tract 1 Normal Liver; Hepatic Injury, Response, and Failure

Diseases of liver. Dr. Mohamed. A. Mahdi 4/2/2019. Mob:

Drug-induced liver injury

Research Article Mortality of Biliary Atresia in Children Not Undergoing Liver Transplantation in Egypt (Single Institutional Study)

PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES I HAVE NOTHING TO DISCLOSE CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017

What to do with abnormal LFTs? Andrew M Smith Hepatobiliary Surgeon

Approach to the Patient with Liver Disease

Patterns of abnormal LFTs and their differential diagnosis

EVALUATION OF ABNORMAL LIVER TESTS

Suspected Isoflurane Induced Hepatitis from Cross Sensitivity in a Post Transplant for Fulminant Hepatitis from Halothane.

Current Management of Biliary Atresia. Janeen Jordan, MD PGY5 Surgery Grand Rounds November 19, 2007

British Liver Transplant Group Pathology meeting September Leeds cases

Liver failure &portal hypertension

Hepatology for the Nonhepatologist

An Approach to Jaundice Block 10. Dr AJ Terblanche Department of Paediatrics and Child Health

DILI PATHOLOGY. PHILIP KAYE November 2017 BSG Pathology Winter Meeting

Lymphoma and Hematological Conditions: I. Lymphoma and Liver Complications of Bone Marrow Transplant

Assessment of Liver Function: Implications for HCC Treatment

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Patterns of abnormal LFTs and their differential diagnosis

Hepatology cases for the generalist. Will Gelson Consultant Hepatologist Addenbrooke s Hospital

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

Learning Objectives. After attending this presentation, participants will be able to:

Management of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France

Drug Induced Liver Disease Role of the Pathologist. Disclosure. DILI can never be excluded. Romil Saxena, MD. Dr. Saxena has nothing to Disclose

Interpreting Liver Function Tests

HEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management

Chapter 18 LIVER BILIARY TRACT

Alpha-1 Liver Disease

Risk stratification in PBC

Primary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants

WEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry

Interpreting Your Tests

Liver Failure. The most severe clinical consequence of liver disease is liver failure:

LIVER SPECIALTY CONFERENCE USCAP Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA

Steatosis/Steatohepatitis

Pathophysiology I Liver and Biliary Disease

Optimal management of auto-immune

NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012

Hepatocellular Carcinoma: Diagnosis and Management

Annals of RSCB Vol. XV, Issue 1

LIVER DISORDERS (PRACTICAL MANAGEMENT) Dr Pok Kern (PK) TAN Gastroenterologist Calvary hospital, ACT 1 st April 2017

Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV

Conflicts of Interest in the last 12 months

Pediatric PSC A children s tale

Non-Cirrhotic Portal Hypertension and Incomplete Septal Cirrhosis. Stefan Hübscher, University of Birmingham, Birmingham B15 2TT, U.K.

The Case of the Limping Poodle

Podcast (Video Recorded Lecture Series): Portal HTN and Derivatives for the USMLE Step One Exam. Ultrasound (w/ doppler) Reversal of flow Portal Vein

11 th Banff Conference on Allograft Pathology - An Update

Case Report Severe Starvation-Induced Hepatocyte Autophagy as a Cause of Acute Liver Injury in Anorexia Nervosa: A Case Report

PORTAL HYPERTENSION An Introduction to the Culprit of Many Liver Failure Complications

Mr Ricky Gellissen Imperial College Healthcare NHS Trust, London, UK

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease

Radiology of hepatobiliary diseases

Key Aspects of Diagnosing Alcoholic Hepatitis. Mark Sonderup University of Cape Town & Groote Schuur Hospital

Liver Cancer And Tumours

BRIDGE THE GAP A Human Pathways Approach to Disease Research

Disclosures. Overview. Case 1. Common Bile Duct Sizes 10/14/2016. General GI + Advanced Endoscopy: NAFLD/Stones/Pancreatitis

Mrs Janet Catt. Pre-Conference Nurse s Course. Royal Free London NHS Foundation Trust. Janet Catt MSc RN Lead Nurse Specialist Practic 12/12/2014

Liver Pathology in the 0bese

Vascular Imaging in the Pediatric Abdomen. Jonathan Swanson, MD

Supplemental Tables. Parasitic Schistosomiasis increase < 1. Genetic Hemochromatosis increase < 1. autoimmune Autoimmune hepatitis (AIH) increase < 1

Prolonged Neonatal Jaundice

Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Alice Fung, MD Oregon Health and Science University

Disorders of the Liver and Pancreas

AASLD: Boston Rob Goldin

Fourth Practical Pathology. Circulatory disturbances

Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP

Case report Idiopathic neonatal hepatitis or extrahepatic biliary atresia? The role of liver biopsy

Situation Report. 1. Highlights

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

Interesting Cases from Liver Tumor Board. Jeffrey C. Weinreb, M.D.,FACR Yale University School of Medicine

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA

Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids. Cholestasis

Fibrosis & Structural Decline of Liver Allografts: what and how to measure & potential underlying causes. Carla Venturi Monteagudo MD, PhD

National Liver EQA Scheme. Open meeting, Glasgow March 24th 2004

TREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC)

Chronic Hepatitis B Infection

Management of acute alcoholic hepatitis

Evaluation Process for Liver Transplant Candidates

Observational Medical Outcomes Partnership

Jaundice. Agnieszka Dobrowolska- Zachwieja, MD, PhD

Management of Chronic Liver Failure/Cirrhosis Complications in Hospitals. By: Dr. Kevin Dolehide

Transcription:

UNIVERSITY OF PRETORIA Hepatic sinusoidal obstruction syndrome due to herbal ingestion in South African children - An 8 year review L. Hendricks, A. Meyer, A. Terblanche Dept of paediatric gastroenterology Steve Biko Academic Hospital 1

No disclaimers or conflicts of interests 2

Introduction Uncommon chronic liver disease Affect children and adults Incidence 1-70% in adults Incidence unknown in children West: Stem cell Transplants, GvHD Africa, Asia, Middle East: Herbal medicine

Pyrrolizidine alkaloids 3% world s plant species contain PA Heliotropium, Senecio, Crotalaria, Symphytum, Tusanqi species Toxic when PA s undergo metabolic oxidation by hepatocytes Damage dose and duration dependent - 4-10 mg/kg/day for 3-7 weeks - WHO: safest intake 1mg/ day in adults

Nakanuma et al, https://doi.org/10.3892/etm.2015.2245 5

Pathophysiology Metabolic oxidation to toxic pyrrole protein adducts Oxidised by cytochrome P450 3A4 biotransformation Results in oxidative stress reaction, mitochondrial injury and apoptosis At sinusoidal level: - PA more selectively toxic to endothelial cells than hepatocytes - Loss of sinusoidal wall integrity with detachment of endothelial lining - Embolization of central zones of hepatic lobule, centrilobular necrosis, perisinusoidal fibrosis, peliosis and nodular regenerative hyperplasia CIRCULATORY OBSTRUCTION PRECEDES HEPATOCYTE DYSFX 6

Objectives Characterize children with SOS due to herbal ingestion Document complications and long term outcomes of patients with SOS

Method Descriptive study Folder review Inclusion criteria - all patients with SOS - 01/01/2008 to 01/04/2016-0 13 years of age at time of presentation - Steve Biko Academic Hospital Paediatric Gastroenterology service Exclusion criteria - incomplete medical records - other causes of chronic liver disease, excluding SOS - > 13 years of age at time of presentation

25 29 patients 20 6 15 10 14 <1 yr age 1-5 yrs age >5 yrs age 5 9 0 male female Median age of presentation 63,5mo

14% Geographical distribution SOS 72% 25 20 15 10 5 0 Mpumalanga Limpopo Gauteng Eastern Cape no. patients

History of ingestion 25 20 15 Ave duration 15 mo 10 5 0 traditional meds pharmaceutical meds homeopathic meds unknown no. of patients

presenting symptoms RUQ pain Upper GI bleed Hepatomegaly Acute liver failure Wasting Jaundice 62% HSM 79% Ascites 80% 0 5 10 15 20 25 30

presenting symptoms RUQ pain Upper GI bleed Hepatomegaly Acute liver failure Wasting presenting symptoms Jaundice HSM Ascites 0 5 10 15 20 25 30

16 Common presenting symptoms 14 12 10 8 6 4 2 0 <1 yr 1-5 yrs >5 yrs

16 Common presenting symptoms 14 12 10 8 6 4 2 0 <1 yr 1-5 yrs >5 yrs

16 Common presenting symptoms 14 12 10 8 6 4 2 0 <1 yr 1-5 yrs >5 yrs

Biochemical markers CMV positive coagulopathy Raised GGT raised AST no. of patients raised ALT raised bili 0 5 10 15 20 25

14 12 12 10 10 8 8 6 6 4 4 2 2 0 Bili > 50 ALT > 30AST > 69 GGT > 22 INR > 1,3 PT > 16 Albumin < 29 0 Bili >50 ALT > 30 AST > 69 GGT > 22 INR > 1,3 PT > 16 Albumin < 29 <1 yr initial bloods 1-5 yrs initial bloods >5 yrs initial bloods <1yr 1-5 yrs > 5 yrs Initial blood results Last recorded blood results

ultrasound 1 6 2 24 ascites thickened GB hepar 22 12 hepatic a RI raised cirrhosis other

14 US findings 12 10 8 6 4 2 0 Ascites Thickened GB Hepar Hepatic artery RI Cirrhosis Other <1 yr 1-5 yrs >5 yrs

Progressive disease Static disease Improvement in condition 100% recovery 10 (35%) 7 (24%) 3 (10%) 5 (17%) Initial PELD 10 Latest PELD 4 Initial PELD 13 Latest PELD 5 Initial PELD 12 Latest PELD - 4 Initial PELD 8 Latest PELD 0 12 10 8 6 4 2 0 outcomes outcomes

6 Age related outcomes 5 4 3 2 1 0 static disease progressive disease improved 100% recovery palliation death <1 yr 1-5 yrs >5 yrs

poor prognostic factors severe ascites weight gain severe hyperbilirubinemia portal vein thrombosis multi organ failure hepatic venous pressure > 20

Poor Px factors multi organ failure portal v thrombosis hyperbilirubinemia ascites 0 2 4 6 8 10 12 >5 yrs 1-5 yrs <1 yr

Conclusion Seems to be more prevalent in rural environments Typically in younger children 0-5 yrs of age Typically present with ascites, jaundice, HSM and PHT - infants seem to present with more complicated disease but are also more likely to respond to supportive treatment PELD scores generally improved on supportive management alone More studies needed to determine incidence, prevalence and prognostic markers Communication imperative!

Thank you!

28

Histology findings ZONAL NECROSIS NARROWING OF SINUSOIDS STEATOSIS BILE DUCT INJURY+NECROSIS VASCULAR INJURY SUBENDOTHELIAL FIBROSIS CENTROLOBULAR NECROSIS 0 1 2 3 4 5 6 7 8 9 >5 yrs 1-5 yrs <1 yr

7 Histology findings compared to PELD scores 6 5 4 3 2 1 0 centrolobular necrosis subendothelial fibrosis vascular injury bile duct injury and necrosis steatosis narrowing of sinusoids zonal necrosis PELD -5 to 5 5 to 10 10 to 15 15 to 20 >20

6 5 4 3 2 1 0 PELD -5 to 5 Initial PELD score 6 to 10 11 to 15 16-20 >20 <1 yr 1-5 yrs >5 yrs Neonates and infants presented with higher PELD scores initially The neonatal and infant group had the most improvement in PELD scores at follow up. >5 yr age group showed deterioration in PELD scores over time. 8 7 6 5 4 3 2 1 0 PELD -5 to 5 Follow up PELD score 6 to 10 11 to 15 16 to 20 >20 <1 yr 1-5 yrs >5 yrs